Weak market demand, environmental threshold raised, API companies forced to turn around

traditional bulk API is the main variety of China's pharmaceutical trade, for export has made an important contribution, but also achieved a number of leading enterprises in the industryHowever, with the change of domestic and foreign market situation, the development of API production enterprises with investment-driven and scale effect as the main mode of growth has encountered bottlenecks and paid the price, overcapacity, resource overdraft, environmental debt, etcare becoming a roadblock to sustainable developmentThe API industry is facing a critical threshold of survival, and the transformation of enterprises is imminentEfB
This edition from today began to publish the "raw material medicine to break through" series of reports, from the industrial difficulties, transformation gains and losses, seeking a way out, combing the development of raw materials, analysis of the transformation of enterprises lessons learned, and the industry to explore the future development of the industryHope that from government departments, industry associations, industrial and commercial enterprises of the knowledge of people to publish insights, clear the transformation and upgrading of pharmaceutical enterprises ideasEfB
After more than a decade of booming, the traditional bulk API market began to show signs of weakness last yearRecently, Xu Ming, vice president of the China Association of Pharmaceutical and Health Products Import and Export Chamber of Commerce, said that since last year, the traditional bulk raw materials trade has no signs of recovery, the future will be in the long-term downward channelChina's traditional bulk API exports prematurely into the growth bottleneck, but the new growth point has not yet been fully formed, the export situation is grimEfB
In fact, the export into the growth bottleneck is only one side of China's bulk API trendWith the tightening of domestic environmental protection policies, clinical restrictions on the use of antibiotics, the traditional bulk apiening domestic demand is also declining, internal and external problems are testing the production of raw materials For these enterprises, has reached the critical moment when we must reflect, adjust the industrial structure and enterprise strategy EfB once popular "big business disease" EfB last January, The H-share "China Pharmaceuticals" of The Company,""listed companies affiliated with Ishiguro Group, changed its name to "Stone Pharmaceutical Group" and injected innovative drugs and research and development of high-quality business The Chinese newspaper of The Stone Pharmaceutical Group showed that, benefiting from innovative drugs, the overall performance increased significantly, the enterprise product structure has been from the past API and formulation ratio of 3:5 to the current 5:5, the enterprise transformation is basically completed EfB
　　Industry insiders said that Ishiguro Group is the leading domestic API production enterprises, but also the rapid pace of transformation of one of the enterprises Due to years of high investment in research and development, some of their preparation products have a better market acceptance, but the pain of corporate transformation will continue EfB
　　As we all know, China's API enterprises to listed companies mainly, its predecessor is mostly state-owned enterprises Shen Xianji, chairman of the expert committee of the China Chemical and Pharmaceutical Industry Association, said that API is the basis for pharmaceutical development China's pharmaceutical industry started late, backward technology, in a long time the state to encourage the development of raw materials to meet the needs of ordinary people State-owned enterprises in this period under the guidance of policy to become the first to benefit from the main body, not only expanded the scale, increased efficiency, but also laid the leading position of the industry EfB
　　The traditional bulk API developed in China is dominated by penicillin series, vitamin series and anti-hot analgesics With the transfer of global API industry in the 1990s, China has gradually become the traditional bulk API production center Public data show that in 1999 China's EXPORT volume of API intermediates was 520.8 million tons, amounting to 2,047 million U.S dollars, while in 2004 the export volume has soared to 10.436 million tons, amounting to 3.756 billion U.S dollars, and the average growth rate of API exports in the past six years has reached more than 17% Among them, penicillin and vitamin C accounted for more than 50% of the world supply EfB
　　"The field of penicillin industrial salt had six price wars before 2006, each time blood-soaked: who has a large tonnage, low cost, who can carry it, and vice versa, is squeezed out of the market One industry insider recalled Through the price war, penicillin and other bulk raw materials and other pharmaceutical production capacity continues to be concentrated, leading enterprises have further consolidated the position Take cephalosporine intermediate 7-ACA, for example, when the domestic production capacity of about 45,000 tons, but the stone pharmaceutical group's production capacity has exceeded 1000 tons In 2005, the global market demand for 7-ACA is about 3000 tons, the capacity of Chinese enterprises alone is sufficient to meet the needs of the global market EfB
　　Aoxing pharmaceutical government consultant, API industry veteran Xu Weifeng believes that it is the unique resource advantages of state-owned enterprises caused by large enterprise disease, the formation of piles of raw materials management situation market demand weak environmental threshold to raise the raw materials enterprises forced to turn around market demand weak environmental threshold to raise the threshold of raw materials pharmaceutical enterprises forced to turn around (2) 1 / 2 1 2 next page end the traditional bulk API is the main variety of China's pharmaceutical trade, for export has made an important contribution to the export, but also achieved a number of leading enterprises in the industry However, with the change of domestic and foreign market situation, the development of API production enterprises with investment-driven and scale effect as the main mode of growth has encountered bottlenecks and paid the price, overcapacity, resource overdraft, environmental debt, etc are becoming a roadblock to sustainable development The API industry is facing a critical threshold of survival, and the transformation of enterprises is imminent EfB
　　This edition from today began to publish the "raw material medicine to break through" series of reports, from the industrial difficulties, transformation gains and losses, seeking a way out, combing the development of raw materials, analysis of the transformation of enterprises lessons learned, and the industry to explore the future development of the industry Hope that from government departments, industry associations, industrial and commercial enterprises of the knowledge of people to publish insights, clear the transformation and upgrading of pharmaceutical enterprises ideas EfB
　　After more than a decade of booming, the traditional bulk API market began to show signs of weakness last year Recently, Xu Ming, vice president of the China Association of Pharmaceutical and Health Products Import and Export Chamber of Commerce, said that since last year, the traditional bulk raw materials trade has no signs of recovery, the future will be in the long-term downward channel China's traditional bulk API exports prematurely into the growth bottleneck, but the new growth point has not yet been fully formed, the export situation is grim EfB
　　In fact, the export into the growth bottleneck is only one side of China's bulk API trend With the tightening of domestic environmental protection policies, clinical restrictions on the use of antibiotics, the traditional bulk apiening domestic demand is also declining, internal and external problems are testing the production of raw materials For these enterprises, has reached the critical moment when we must reflect, adjust the industrial structure and enterprise strategy EfB once popular "big business disease" EfB last January, The H-share "China Pharmaceuticals" of The Company,""listed companies affiliated with Ishiguro Group, changed its name to "Stone Pharmaceutical Group" and injected innovative drugs and research and development of high-quality business The Chinese newspaper of The Stone Pharmaceutical Group showed that, benefiting from innovative drugs, the overall performance increased significantly, the enterprise product structure has been from the past API and formulation ratio of 3:5 to the current 5:5, the enterprise transformation is basically completed EfB
　　Industry insiders said that Ishiguro Group is the leading domestic API production enterprises, but also the rapid pace of transformation of one of the enterprises Due to years of high investment in research and development, some of their preparation products have a better market acceptance, but the pain of corporate transformation will continue EfB
　　As we all know, China's API enterprises to listed companies mainly, its predecessor is mostly state-owned enterprises Shen Xianji, chairman of the expert committee of the China Chemical and Pharmaceutical Industry Association, said that API is the basis for pharmaceutical development China's pharmaceutical industry started late, backward technology, in a long time the state to encourage the development of raw materials to meet the needs of ordinary people State-owned enterprises in this period under the guidance of policy to become the first to benefit from the main body, not only expanded the scale, increased efficiency, but also laid the leading position of the industry EfB
　　The traditional bulk API developed in China is dominated by penicillin series, vitamin series and anti-hot analgesics With the transfer of global API industry in the 1990s, China has gradually become the traditional bulk API production center Public data show that in 1999 China's EXPORT volume of API intermediates was 520.8 million tons, amounting to 2,047 million U.S dollars, while in 2004 the export volume has soared to 10.436 million tons, amounting to 3.756 billion U.S dollars, and the average growth rate of API exports in the past six years has reached more than 17% Among them, penicillin and vitamin C accounted for more than 50% of the world supply EfB
　　"The field of penicillin industrial salt had six price wars before 2006, each time blood-soaked: who has a large tonnage, low cost, who can carry it, and vice versa, is squeezed out of the market One industry insider recalled Through the price war, penicillin and other bulk raw materials and other pharmaceutical production capacity continues to be concentrated, leading enterprises have further consolidated the position Take cephalosporine intermediate 7-ACA, for example, when the domestic production capacity of about 45,000 tons, but the stone pharmaceutical group's production capacity has exceeded 1000 tons In 2005, the global market demand for 7-ACA is about 3000 tons, the capacity of Chinese enterprises alone is sufficient to meet the needs of the global market EfB
　　Aoxing pharmaceutical government consultant, API industry veteran Xu Weifeng believes that it is the unique resource advantages of state-owned enterprises caused by large enterprise disease, the formation of piles of raw materials management situation